Injected progestogen and lactation.

Area of Science:

• Reproductive Endocrinology
• Lactation Physiology
• Contraception

Background:

• Postpartum women require effective and safe contraception methods.
• Hormonal contraceptives are widely used but concerns exist regarding their impact on lactation.
• Long-acting injectable progestogens are a potential option for postpartum contraception.

Purpose of the Study:

• To evaluate the efficacy of norethisterone enanthate and medroxyprogesterone acetate for postpartum fertility control.
• To assess the impact of these agents on milk production and lactation duration.
• To monitor infant growth and identify any significant side effects.

Main Methods:

• Prospective study comparing injectable contraceptives with a control group.
• Norethisterone enanthate (200 mg every 84 days) and medroxyprogesterone acetate (150 mg every three months) administered postpartum.
• Monitoring of milk availability, lactation duration, infant weight gain, and maternal side effects.

Main Results:

• Both norethisterone enanthate and medroxyprogesterone acetate demonstrated complete effectiveness in preventing pregnancy.
• No adverse effects on milk volume or lactation duration were observed; higher milk availability and infant weight gain noted in treated groups from month three.
• A slight decrease in milk protein was observed across groups, attributed to dietary factors. Amenorrhea was the primary noted side effect.

Conclusions:

• Long-acting injectable progestogens are highly effective for postpartum contraception.
• These agents do not compromise breastfeeding and may enhance infant growth.
• Amenorrhea is a common, non-serious side effect, with no other significant adverse events reported.